Targeted T cell receptor gene editing provides predictable T cell product function for immunotherapy
Thomas Müller(Johns Hopkins University), Dirk H. Busch(German Center for Infection Research), Simon Grassmann(Technical University of Munich), Sebastian Jarosch(Boehringer Ingelheim (Germany)), Peter Steinberger(University of Vienna), Manuel Effenberger(Institute of Medical Microbiology and Hygiene), Monika Hammel(Institute of Medical Microbiology and Hygiene), M. Zeeshan Chaudhry(The University of Queensland), Immanuel Andrä(Technical University of Munich), Kilian Schober(Friedrich-Alexander-Universität Erlangen-Nürnberg), Luka Čičin‐Šain(German Center for Infection Research), Michael Neuenhahn(Institute of Medical Microbiology and Hygiene)
Cited by 8
Related Papers
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
|European Journal of Immunology|2019|1k
Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry
|Nature Communications|2016|727
Guidelines for the use of flow cytometry and cell sorting in immunological studies <sup>*</sup>
|European Journal of Immunology|2017|554
Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
|Journal of Clinical Oncology|2011|551